Results 101 to 110 of about 11,898 (160)

Assessing the value of oligoclonal band count in multiple sclerosis: insights from a large cohort analysis. [PDF]

Front Neurol
Jendretzky KF, Wurster U, Konen FF, Döring K, Friedrich JF, Nay S, Möhn N, Grote-Levi L, Hümmert MW, Sühs KW, Schwenkenbecher P, Gingele S, Skripuletz T.   +12 more
europepmc   +1 more source

Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses. [PDF]

Front Immunol
Curtin R, Velmurugu Y, Dibba F, Hao Y, Nyovanie S, Lopez A, Mieles D, Ng C, Perdomo K, Scott N, Lewin JB, Avila RL, Smrtka J, Patskovsky Y, Howard J, Silverman GJ, Krogsgaard M.   +16 more
europepmc   +1 more source

Diminishing returns of disease-modifying treatment in older participants of multiple sclerosis clinical trials. [PDF]

Mult Scler
Strijbis E, Mostert J, D'Haeseleer M, Moral E, Brieva Ruiz L, Comtois J, Killestein J, Repovic P, McPherson T, Cutter G, Koch M.   +10 more
europepmc   +1 more source

Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens. [PDF]

J Neurol
Konitsioti AM, Schweitzer F, Johannis W, Steffen F, Bittner S, Fink GR, Schroeter M, Warnke C.   +7 more
europepmc   +1 more source

No association between the wearing-off effect and α4-integrin receptor saturation in natalizumab treated patients with relapsing-remitting multiple sclerosis. [PDF]

Neurotherapeutics
Freeman SA, Rual C, Biotti D, Lepetit M, Le Berre J, Ferrara K, Treiner E, Ciron J.   +7 more
europepmc   +1 more source

Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis. [PDF]

J Neurol Neurosurg Psychiatry
Gelissen LMY, Toorop AA, Schipper PM, Hoitsma E, Zeinstra EMPE, van Rooij LC, van Munster CEP, Vennegoor A, Mostert J, Wokke B, Kalkers NF, Hoogervorst ELJ, van Eijk J, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige LGF, Kloosterziel ME, Arnoldus EPJ, Bouvy WH, Strijbis EM, Oosten BV, De Jong BA, Uitdehaag BMJ, Lissenberg-Witte BI, Loeff FC, Rispens T, Killestein J, van Kempen ZLE.   +30 more
europepmc   +1 more source

Comparative Efficacy of Ublitixumab Versus Natalizumab in the Treatment of Relapsing and Remitting Multiple Sclerosis. [PDF]

Cureus
Chitturi SV, Amith Priyansu J, Sadhu A, Ramisetty H, Pallapothu MR, Kogantii D.   +5 more
europepmc   +1 more source

Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab. [PDF]

BMJ Neurol Open
Høgestøl EA, Brustad ÅW, Celius EG, Meling M, Berg-Hansen P, Berg-Hansen P, Kro GB, König M, Schanke Y, Halvorsen B, Warren DJ, Gehin JE, Bolstad N, Nygaard GO.   +13 more
europepmc   +1 more source

Systematic Review of Monoclonal Antibody Therapies in Relapsing Multiple Sclerosis: Comparator-Stratified Analysis of Relapse and Disability Outcomes. [PDF]

Med Sci (Basel)
Ciubotaru A, Grosu C, Maștaleru A, Constantinescu V, Alexa D, Covali R, Riscanu L, Bilcu RV, Cucu LE, Gațcan C, Socolov-Mihaita SA, Lăcătușu D, Crivoi F, Vamanu A, Patrascu A, Ignat EB.   +15 more
europepmc   +1 more source

Immunogenicity of Hepatitis B Virus Vaccination in Relapsing-Remitting Multiple Sclerosis Patients Under Immunocompromising Treatment. [PDF]

Int J Mol Sci
Cruces-Párraga J, Muñoz-Jurado A, Escribano BM, Martín-Hersog FA, Triguero-Ortiz C, Carmona-Medialdea C, Túnez I, Caballero-Villarraso J, Agüera-Morales E.   +8 more
europepmc   +1 more source